LB Pharmaceuticals Inc (LBRX)
| Market Cap | 903.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.21M |
| Shares Out | 28.68M |
| EPS (ttm) | -3.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,409 |
| Open | 31.81 |
| Previous Close | 31.81 |
| Day's Range | 30.62 - 33.00 |
| 52-Week Range | 13.36 - 33.47 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 46.60 (+47.89%) |
| Earnings Date | May 6, 2026 |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $46.6, which is an increase of 47.89% from the latest price.
News
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizo...
LB Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
LB-102, a novel CNS therapeutic, is advancing through fully funded phase III and II trials in schizophrenia, bipolar depression, and adjunctive MDD, with data readouts expected from 2027 to 2029. The drug's differentiated mechanism, strong safety profile, and robust efficacy position it competitively for multiple indications.
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizo...
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia Multiple SIRS presentations underscore the potential of LB-...
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase ...
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week...
LB Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum
LB-102 is advancing through late-stage trials for schizophrenia, bipolar depression, and MDD, with robust Phase 2 efficacy and a strong safety profile. The program is fully funded through Q2 2029, with strategic trial designs and risk mitigation measures in place to support successful outcomes.
LB Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
LB-102 is advancing through late-stage clinical trials for schizophrenia, bipolar depression, and adjunctive MDD, supported by recent capital raises. The molecule demonstrates robust efficacy, cognitive benefits, and a favorable safety profile, with commercial and manufacturing preparations underway.
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizo...
LB Pharmaceuticals to Participate in Upcoming March Investor Events
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizo...
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Cou...
LB Pharmaceuticals Announces $100.0 Million Private Placement
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizop...
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ...
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for sc...
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for sc...
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000® Index and t...
LB Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
Secured $300M in a tough IPO market, enabling phase III schizophrenia and phase II bipolar depression trials, with top-line schizophrenia data expected in 2027. LB-102 shows strong efficacy, low EPS, and differentiation in cognition and negative symptoms.
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief Executive Officer, will present at ...
LB Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
LB-102, a novel antipsychotic, showed strong efficacy and safety in phase II schizophrenia trials, with phase III and bipolar depression studies underway. The company is leveraging robust trial design, a differentiated safety profile, and a $300M IPO to advance toward key data readouts by 2028.
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for sc...
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief Executive Officer, will present at ...
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced financial results for the third quarter ended on September 30,...
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice Presi...
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that three posters featuring new and previously reported analy...
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its B...